Consequences of stopping mavacamten after taking it for three months

Mavacamten (mavacamten) is a new drug used to treat hypertrophic cardiomyopathy (HCM). Its main function is to inhibit cardiac myosin, thereby relieving cardiac obstruction and improving patients' symptoms. When patients stop taking Malvacartide, especially after three months, they may experience a range of consequences that depend on the individual patient's condition, severity of illness and response to the drug.

Patients may experience a recurrence or worsening of symptoms after stopping the drug. Mavaceta can effectively improve the symptoms of HCM patients, such as dyspnea, chest pain and fatigue. When the medication is stopped, these symptoms may reappear, negatively affecting the patient's quality of life. Specific manifestations may include decreased exercise tolerance, limitations in daily activities, and the return of heart failure-related symptoms.

Hemodynamic conditions of the heart may worsen after discontinuation of the drug. Mavaceta improves the blood flow status of the heart by reducing the pressure gradient in the left ventricular outflow tract. If patients do not take additional treatment after discontinuation of the drug, their LVOT (left ventricular outflow tract) gradient may increase again, resulting in further impairment of cardiac function. This situation may require medical intervention, such as restarting medications or considering other treatments.

In addition, the patient's psychological and emotional state may also be affected after stopping the drug. ManyHCM patients experience improvement in symptoms and feel psychologically positive and optimistic during treatment with Mavacartide. After discontinuing medication, as symptoms return, patients may feel anxious, depressed, or helpless, affecting their overall mental health. Therefore, doctors and nursing teams should provide adequate support and guidance to patients after they stop taking medications to help them cope with possible psychological stress.

Reference materials:https://consultqd.clevelandclinic.org/rems-update-mavacamten-still-effective-in-treating-real-world-patients-with-hcm